ERBB2 and neoplasm: Although the loss of B cells can be managed with intravenous immunoglobulin infusions [135], targeting more abundant molecules, e.g., human epidermal growth factor receptor 2 (HER2), may lead to serious on-target off-tumor cytotoxicity as observed in a clinical trial of HER2-directed CAR where severe potentially fatal side effects were reported [136].